纳武利尤单抗联合伊匹木单抗治疗转移性肾细胞癌的安全性与疗效:CheckMate 016研究
开放标签、平行队列、剂量递增的I期CheckMate 016研究评估纳武利尤单抗联合伊匹木单抗治疗转移性肾细胞癌的安全性与疗效。N3I1与N1I3组各47例,确认客观缓解率均为40.4%,2年总生存率分别为67.3%与69.6%,3-4级治疗相关不良事件发生率分别为38.3%与61.7%。
要点
- N3I1与N1I3组确认客观缓解率均为40.4%,中位随访22.3个月。
- 2年总生存率N3I1组67.3%,N1I3组69.6%。
- 3-4级治疗相关不良事件N3I1组38.3%,N1I3组61.7%。
核心结论
- 纳武利尤单抗联合伊匹木单抗治疗转移性肾细胞癌显示出可控的安全性、显著的抗肿瘤活性、持久缓解及有前景的总生存。
研究设计与样本
- 开放标签、平行队列、剂量递增的I期CheckMate 016研究,评估纳武利尤单抗联合伊匹木单抗及纳武利尤单抗联合酪氨酸激酶抑制剂治疗转移性肾细胞癌。
- 患者接受纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg(N3I1)、纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg(N1I3)或纳武利尤单抗3 mg/kg联合伊匹木单抗3 mg/kg(N3I3),每3周一次共4剂,随后纳武利尤单抗3 mg/kg每2周一次单药治疗直至进展或毒性。
- N3I3组6例患者因剂量限制性毒性或其他原因在分析时均被删失;N3I1和N1I3组各47例患者接受治疗,两组基线特征均衡。
主要发现
- N3I1组和N1I3组的3-4级治疗相关不良事件发生率分别为38.3%和61.7%。
- 中位随访22.3个月时,N3I1组和N1I3组的确认客观缓解率均为40.4%,持续缓解患者比例分别为42.1%和36.8%。
- N3I1组和N1I3组的2年总生存率分别为67.3%和69.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimumab in combination, and nivolumab plus a tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC). Safety and efficacy results from the nivolumab plus ipilimumab arms of the study are presented. Patients and Methods Patients with mRCC received intravenous nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3I1), nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (N1I3), or nivolumab 3 mg/kg plus ipilimumab 3 mg/kg (N3I3) every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks until progression or toxicity. End points included safety (primary), objective response rate, and overall survival (OS). Results All patients in the N3I3 arm (n = 6) were censored at the time of analysis as a result of dose-limiting toxicity or other reasons. Forty-seven patients were treated in both the N3I1 and the N1I3 arm, and baseline patient characteristics were balanced between arms. Grade 3 to 4 treatment-related adverse events were reported in 38.3% and 61.7% of the patients in the N3I1 and N1I3 arms, respectively. At a median follow-up of 22.3 months, the confirmed objective response rate was 40.4% in both arms, with ongoing responses in 42.1% and 36.8% of patients in the N3I1 and N1I3 arms, respectively. The 2-year OS was 67.3% and 69.6% in the N3I1 and N1I3 arms, respectively. Conclusion Nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising OS in patients with mRCC.
引用
- Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017. PMID: 28678668. doi:10.1200/JCO.2016.72.1985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。